Abstract - 2018 - Research and Practice in Thrombosis and Haemostasis
Clinical Decision-Making In ITP: Timing Treatment Initiation And Therapy Goals
An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.
Once immune thrombocytopenic purpura (ITP) is diagnosed and other causes of thrombocytopenia have been excluded, treatment decisions depend on the patient's platelet count, symptoms, and comorbidities. If a patient has a platelet count above 20,000 to 30,000 without active bleeding, treatment may not be necessary—close monitoring might be sufficient. However, if there is any evidence of bleeding (e.G., nosebleeds, hemorrhoid-related bleeding, or petechiae), treatment becomes necessary even at these higher platelet levels. Comorbid conditions, such as heart disease requiring antiplatelet therapy, can also influence the decision to initiate treatment sooner to avoid bleeding risks.
For patients with very low platelet counts—especially in the single digits—and active bleeding, rapid inpatient intervention is required. These cases are considered urgent due to the risk of hemorrhagic complications. First-line treatment options in such scenarios include high-dose steroids or intravenous immunoglobulin (IVIG) to quickly raise platelet levels and stabilize the patient. In more stable outpatient cases, oral steroids remain the most common approach. Dexamethasone is preferred for its quick action and short treatment duration (typically four days), while prednisone is used for longer courses but comes with a greater risk of side effects like fluid retention, hyperglycemia, or immunosuppression—especially concerning for patients with diabetes or cardiovascular conditions.
Other treatment considerations include choosing between short-term therapies that offer the possibility of treatment-free remission and long-term options requiring ongoing management. Some patients may benefit from therapies like rituximab, which is administered over a short course, while others may need regular subcutaneous injections requiring frequent clinic visits. Ultimately, treatment plans are individualized based on factors like the patient's overall health, convenience, access to care, and goals of therapy, aiming to balance efficacy with minimizing treatment burden and potential adverse effects.
NewsletterStay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Diagnostic And Patient Education Strategies In ITP
A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and bleeding symptoms like nosebleeds, bruising, and petechiae.
ITP remains a diagnosis of exclusion with no specific confirmatory tests available. Clinicians must rule out other causes of thrombocytopenia including medication effects, viral infections, coexisting autoimmune diseases, and lymphoid proliferative disorders like CLL or low-grade lymphomas through comprehensive laboratory testing and serological examination.
There is no reliable way to predict the severity or course of ITP through laboratory testing, physical examination, or clinical symptoms. Each patient's disease has its own unique pattern and personality, sometimes presenting as mild before becoming severe, or starting severely before moderating. This unpredictability necessitates individualized treatment approaches.
Patient education is crucial following diagnosis, including explaining the autoimmune nature of ITP and potential symptoms. Key bleeding signs to watch for include mucosal bleeding sites such as nosebleeds (epistaxis), gum bleeding (gingival bleeding), heavy menstrual periods in women, easy bruising, and petechiae - small red rashes particularly on lower extremities caused by tiny blood vessels breaking due to inadequate platelet function.
NewsletterStay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
ITP In Children: Shifting Management Strategies?
Access DeniedYou don't have permission to access "http://www.Medpagetoday.Com/resource-centers/chronic-immune-thrombocytopenia-meeting-challenge/itp-children-shifting-management-strategies/3116" on this server.
Reference #18.11463917.1758509280.6b1c839
https://errors.Edgesuite.Net/18.11463917.1758509280.6b1c839
Comments
Post a Comment